One Novel Urinary Biomarkers of Acute Kidney Injury in Patients After Allogeneic Hematopoetic Stem Cell Transplantation.

• Kidney damage remains a significant complication of HCT affecting the mortality of transplant patients. • Identifying risk factors and markers of kidney injury, understanding the causes and appropriate treatment of kidney injury are important to the safety of the HSCT procedure. • RBP4 was significantly higher in patients after HSCT when compared to healthy volunteers. • Nephroprotective strategies are key to prevent chronic kidney disease. Hematopoietic stem cell transplantation could be complicated by acute kidney injury and chronic kidney disease. It may be due to either previous chemotherapy or exposure to a variety of nephrotoxic drug or other causes. The aim of the study was to assess biomarkers of kidney injury in patients at least 3 months after hematopoetic stem cell transplantation (HSCT) under ambulatory care of the Hematology, Transplantation and Internal Medicine Department. We studied 80 prevalent patients after allogeneic HSCT and 32 healthy volunteers to obtain normal ranges of biomarkers. In this cross-sectional study we assessed retinol-binding protein 4 (RBP4), a biomarker of kidney injury in urine using commercially available assays. It was significantly higher in patients after HSCT when compared to healthy volunteers. When we divided patients according to kidney function (below and over 60 mL/min/1.72 m2), we found that the concentration of RBP4 was significantly higher in 23 patients with chronic kidney disease stage 3 compared to patients with estimated glomerular filtration (eGFR) over 60 mL/min/1.72 m2. In univariate correlations RBP4 was positively related to serum creatinine (r = 0.34, P <.01) and inversely to eGFR (r = −0.20, P <.05). Patients after allogeneic HSCT despite normal or near normal kidney function show evidence of kidney injury. [ABSTRACT FROM AUTHOR]